Abstract 5243: Novel non-COX inhibitory sulindac derivative with β-catenin suppressing activity reduces the formation of colorectal adenomas and adenocarcinomas in the <i>APC</i> <i>+/min-FCCC</i> mouse model
Kevin J. Lee(University of Alabama at Birmingham), Wen‐Chi Chang(National Cheng Kung University), Adam B. Keeton(Washburn University), Ashley S. Lindsey(USA Mitchell Cancer Institute), Joel Andrews(USA Mitchell Cancer Institute), Gary A. Piazza(Auburn University), Harry S. Cooper(Fox Chase Cancer Center), Xi Chen(Tongji University), Verónica Ramírez‐Alcántara(USA Mitchell Cancer Institute), Jacob Valiyaveettil(USA Mitchell Cancer Institute), Margie L. Clapper
Cited by 0
Related Papers
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Metabolic gene polymorphism frequencies in control populations.
|PubMed|2001|847
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846